Laird Norton Wetherby Trust Company’s Bristol-Myers Squibb BMY Stock Holding History

Laird Norton Wetherby Trust Company’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.47M	Sell	42,882 -410	-0.9%	-$23.5K	0.05%	295
2026 Q1	$2.63M	Sell	43,292 -13,650	-24%	-$796K	0.06%	263
2025 Q4	$3.07M	Buy	+56,942	New	+$2.74M	0.06%	236
2023 Q2	–	Sell	-3,501	Closed	-$243K	–	117
2023 Q1	$243K	Hold	3,501	–	–	0.03%	97
2022 Q4	$252K	Buy	+3,501	New	+$264K	0.04%	95
2022 Q3	–	Sell	-5,593	Closed	-$433K	–	78
2022 Q2	$433K	Sell	5,593 -2,669	-32%	-$203K	0.05%	66
2022 Q1	$603K	Sell	8,262 -178	-2%	-$12K	0.06%	97
2021 Q4	$526K	Buy	8,440 +108	+1%	+$6.33K	0.05%	104
2021 Q3	$493K	Sell	8,332 -144	-2%	-$9.48K	0.05%	99
2021 Q2	$566K	Sell	8,476 -1,294	-13%	-$84.4K	0.06%	81
2021 Q1	$606K	Hold	9,770	–	–	0.07%	79
2020 Q4	$606K	Buy	+9,770	New	+$601K	0.07%	77

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Laird Norton Wetherby Trust Company's BMY Position: Q2 2026 in Review

Laird Norton Wetherby Trust Company reduced its Bristol-Myers Squibb (BMY) stake by 0.95% in Q2 2026, selling an estimated $23.5K and leaving 42,882 shares worth $2.47M. The position accounts for 0.05% of the portfolio, ranked #295.

Laird Norton Wetherby Trust Company first reported a position in BMY in Q4 2020 and has held it in 12 quarters since. The position peaked at $3.07M in Q4 2025. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Laird Norton Wetherby Trust Company held 42,882 shares of Bristol-Myers Squibb worth $2.47M as of Q2 2026.
Laird Norton Wetherby Trust Company sold 410 Bristol-Myers Squibb shares in Q2 2026, an estimated $23.5K.
Bristol-Myers Squibb made up 0.05% of Laird Norton Wetherby Trust Company's portfolio in Q2 2026, its #295 holding.
Laird Norton Wetherby Trust Company first reported a position in Bristol-Myers Squibb in Q4 2020 and has held it in 12 quarters since.
Laird Norton Wetherby Trust Company's Bristol-Myers Squibb position peaked at $3.07M in Q4 2025.
2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Laird Norton Wetherby Trust Company's 13F filing for Q2 2026, filed 14 Aug 2026.